Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

In this article we will help you to know more about the infusion therapy, about its process, precautions to be taken care ...

No significant differences in the risk of myocardial infarction, ischemic stroke, or cardiovascular-related death were observed in patients with psoriasis or psoriatic ... adults with PsO and PsA who ...

The company already markets the biosimilar under the brand name Abeymy in Europe and Canada. Shreehas Tambe, CEO and Managing Director of Biocon Biologics, described the approval as a “significant ...

NEW YORK: Long-threatened tariffs from US President Donald Trump have plunged the country into trade wars abroad - all while on-again, off-again new levies continue to escalate uncertainty ...

A lower Charlson comorbidity index, no psoriatic arthritis, a family history of psoriasis, BMI within normal limits, and a lower triglyceride to high-density lipoprotein cholesterol ratio were linked ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...